Vol 80, No 3 (2022)
Review paper
Published online: 2022-03-22

open access

Page views 5864
Article views/downloads 1206
Get Citation

Connect on Social Media

Connect on Social Media

Specific characteristics of STEMI in COVID-19 patients and their practical implications

Mauro Gitto12, Laura Novelli12, Bernhard Reimers12, Gianluigi Condorelli12, Giulio G Stefanini12
Pubmed: 35334109
Kardiol Pol 2022;80(3):266-277.

Abstract

ST-elevation myocardial infarction (STEMI) is one of the cardiac emergencies whose management has been most challenged by the COVID-19 pandemic. Patients presenting with the “lethal combo” of STEMI and concomitant SARS-CoV-2 infection have faced dramatic issues related to the need for self-isolation, systemic inflammation with multi-organ disease and difficulties to obtain timely diagnosis and treatment. The interplay between these and other factors has partly neutralized the major advances in STEMI care achieved in the last decades, significantly impairing prognosis in these patients. In the present review article, we will provide an overview on mechanisms of myocardial injury, specific clinical and angiographic characteristics and contemporary management in different settings of STEMI patients with COVID-19, alongside the inherent implications in terms of in-hospital mortality and short-term clinical outcomes.

References

  1. Giustino G, Croft LB, Stefanini GG, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020; 76(18): 2043–2055.
  2. Chung MK, Zidar DA, Bristow MR, et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res. 2021; 128(8): 1214–1236.
  3. Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021; 18(3): 169–193.
  4. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020; 2(11): 2102–2108.
  5. Vogel B, Claessen BE, Arnold SV, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers. 2019; 5(1): 39.
  6. Nowbar AN, Gitto M, Howard JP, et al. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019; 12(6): e005375.
  7. Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007; 28(10): 1205–1210.
  8. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004; 351(25): 2611–2618.
  9. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020; 5(7): 831–840.
  10. Fröbert O, Götberg M, Erlinge D, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation. 2021; 144(18): 1476–1484.
  11. Xiang D, Xiang X, Zhang W, et al. Management and outcomes of patients with STEMI during the COVID-19 pandemic in China. J Am Coll Cardiol. 2020; 76(11): 1318–1324.
  12. Bangalore S, Halista M. STEMI outcomes in the era of COVID-19: reaffirmation of an unfortunate reality. EuroIntervention. 2021; 16(17): 1379–1380.
  13. Stefanini GG, Montorfano M, Trabattoni D, et al. ST-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020; 141(25): 2113–2116.
  14. Li X, Guan Bo, Su T, et al. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart. 2020; 106(15): 1142–1147.
  15. Stefanini GG, Chiarito M, Ferrante G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020; 106(19): 1512–1518.
  16. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020; 55(5).
  17. Shi S, Qin Mu, Shen Bo, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5(7): 802–810.
  18. Wibowo A, Pranata R, Akbar MR, et al. Prognostic performance of troponin in COVID-19: A diagnostic meta-analysis and meta-regression. Int J Infect Dis. 2021; 105: 312–318.
  19. Metkus TS, Sokoll LJ, Barth AS, et al. Myocardial injury in severe COVID-19 compared with non-covid-19 acute respiratory distress syndrome. Circulation. 2021; 143(6): 553–565.
  20. Jirak P, Larbig R, Shomanova Z, et al. Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study. ESC Heart Fail. 2021; 8(1): 37–46.
  21. Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116(6): 1097–1100.
  22. Evans PC, Rainger GEd, Mason JC, et al. Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science. Cardiovasc Res. 2020; 116(14): 2177–2184.
  23. Roberts KA, Colley L, Agbaedeng TA, et al. Vascular manifestations of COVID-19 — thromboembolism and microvascular dysfunction. Front Cardiovasc Med. 2020; 7: 598400.
  24. Yin J, Wang S, Liu Y, et al. Coronary microvascular dysfunction pathophysiology in COVID-19. Microcirculation. 2021; 28(7): e12718.
  25. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; 116(10): 1666–1687.
  26. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018; 72(18): 2231–2264.
  27. Choudry FA, Hamshere SM, Rathod KS, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020; 76(10): 1168–1176.
  28. Alfano G, Fontana F, Mori G, et al. Acid base disorders in patients with COVID-19. Int Urol Nephrol. 2022; 54(2): 405–410.
  29. Rodriguez-Leor O, Cid Alvarez AB, Pérez de Prado A, et al. In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients. EuroIntervention. 2021; 16(17): 1426–1433.
  30. D'Ascenzi F, Cameli M, Forni S, et al. Reduction of emergency calls and hospitalizations for cardiac causes: effects of COVID-19 pandemic and lockdown in tuscany region. Front Cardiovasc Med. 2021; 8: 625569.
  31. Santi L, Golinelli D, Tampieri A, et al. Non-COVID-19 patients in times of pandemic: Emergency department visits, hospitalizations and cause-specific mortality in Northern Italy. PLoS One. 2021; 16(3): e0248995.
  32. Mafham MM, Spata E, Goldacre R, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020; 396(10248): 381–389.
  33. De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020; 41(22): 2083–2088.
  34. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of COVID-19. N Engl J Med. 2020; 382(21): 2049–2055.
  35. Rodríguez-Leor O, Cid-Álvarez B, Pérez de Prado A, et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Rev Esp Cardiol (Engl Ed). 2020; 73(12): 994–1002.
  36. Fabris E, Bessi R, De Bellis A, et al. COVID-19 impact on ST-elevation myocardial infarction incidence rate in a Italian STEMI network: a U-shaped curve phenomenon. J Cardiovasc Med (Hagerstown). 2021; 22(5): 344–349.
  37. Niccoli G, Luescher TF, Crea F. Decreased myocardial infarction admissions during COVID times: what can we learn? Cardiovasc Res. 2020; 116(10): e126–e128.
  38. Case BC, Yerasi C, Forrestal BJ, et al. Comparison of characteristics and outcomes of patients with acute myocardial infarction with versus without coronarvirus-19. Am J Cardiol. 2021; 144: 8–12.
  39. Kite TA, Ludman PF, Gale CP, et al. International prospective registry of acute coronary syndromes in patients with COVID-19. J Am Coll Cardiol. 2021; 77(20): 2466–2476.
  40. Saad M, Kennedy KF, Imran H, et al. Association between COVID-19 diagnosis and in-hospital mortality in patients hospitalized with ST-segment elevation myocardial infarction. JAMA. 2021; 326(19): 1940–1952.
  41. Garcia S, Dehghani P, Grines C, et al. Initial Findings From the North American COVID-19 Myocardial Infarction Registry. J Am Coll Cardiol. 2021; 77(16): 1994–2003.
  42. Price-Haywood EG, Burton J, Fort D, et al. Hospitalization and mortality among black patients and white patients with COVID-19. N Engl J Med. 2020; 382(26): 2534–2543.
  43. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York City. N Engl J Med. 2020; 382(24): 2372–2374.
  44. Krishnan L, Ogunwole SM, Cooper LA. Historical insights on coronavirus disease 2019 (COVID-19), the 1918 influenza pandemic, and racial disparities: illuminating a path forward. Ann Intern Med. 2020; 173(6): 474–481.
  45. The plight of essential workers during the COVID-19 pandemic. Lancet. 2020; 395(10237): 1587.
  46. Muñoz-Price LS, Nattinger AB, Rivera F, et al. Racial disparities in incidence and outcomes among patients with COVID-19. JAMA Netw Open. 2020; 3(9): e2021892.
  47. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
  48. Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020; 180(10): 1345–1355.
  49. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280.e8.
  50. Swamy S, Koch CA, Hannah-Shmouni F, et al. Hypertension and COVID-19: Updates from the era of vaccines and variants. J Clin Transl Endocrinol. 2022; 27: 100285.
  51. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020; 382(17): 1653–1659.
  52. Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2: a double-edged sword. Circulation. 2020; 142(5): 426–428.
  53. Carrick D, Haig C, Maznyczka AM, et al. Hypertension, microvascular pathology, and prognosis after an acute myocardial infarction. Hypertension. 2018; 72(3): 720–730.
  54. McMaster WG, Kirabo A, Madhur MS, et al. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015; 116(6): 1022–1033.
  55. Pranata R, Henrina J, Raffaello WM, et al. Diabetes and COVID-19: The past, the present, and the future. Metabolism. 2021; 121: 154814.
  56. Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021; 17(1): 11–30.
  57. Cui J, Liu Y, Li Y, et al. Type 2 diabetes and myocardial infarction: recent clinical evidence and perspective. Front Cardiovasc Med. 2021; 8: 644189.
  58. Hariyanto TI, Kurniawan A, Hariyanto TI, et al. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020; 14(5): 1463–1465.
  59. Atmosudigdo IS, Lim MA, Radi B, et al. Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression. J Clin Exp Hepatol. 2021 [Epub ahead of print]; 14: 1179551421990675.
  60. Vuorio A, Lassila R, Kovanen PT. Hypercholesterolemia and COVID-19: statins for lowering the risk of venous thromboembolism. Front Cardiovasc Med. 2021; 8: 711923.
  61. Tsigaris P, Teixeira da Silva JA. Smoking Prevalence and COVID-19 in Europe. Nicotine Tob Res. 2020; 22(9): 1646–1649.
  62. Alla F, Berlin I, Nguyen-Thanh V, et al. Tobacco and COVID-19: a crisis within a crisis? Can J Public Health. 2020; 111(6): 995–999.
  63. Farsalinos K, Barbouni A, Niaura R, et al. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med. 2020; 15(5): 845–852.
  64. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23): 2950–2973.
  65. Gitto M, Gentile F, Nowbar AN, et al. Gender-Related differences in clinical presentation and angiographic findings in patients with ischemia and no obstructive coronary artery disease (INOCA): a single-center observational registry. Int J Angiol. 2020; 29(4): 250–255.
  66. Gitto M, Saito Y, Taoutel R, et al. Angiographic lesion discordance in women presenting with ischemic heart disease: comparison of visual assessment, quantitative coronary angiography, and quantitative flow ratio. J Invasive Cardiol. 2022; 34(3): E202–E209.
  67. Hamadeh A, Aldujeli A, Briedis K, et al. Characteristics and outcomes in patients presenting with COVID-19 and ST-segment elevation myocardial infarction. Am J Cardiol. 2020; 131: 1–6.
  68. Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021; 76(4): 412–420.
  69. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010; 10(2): 83–92.
  70. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018; 378(4): 345–353.
  71. Welt FGP, Shah PB, Aronow HD, et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI. J Am Coll Cardiol. 2020; 75(18): 2372–2375.
  72. Jing ZC, Zhu HD, Yan XW, et al. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heart J. 2020; 41(19): 1791–1794.
  73. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment elevation in patients with COVID-19 — a case series. N Engl J Med. 2020; 382(25): 2478–2480.
  74. Popovic B, Varlot J, Metzdorf PA, et al. Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection. Catheter Cardiovasc Interv. 2021; 97(3): E319–E326.
  75. Lindahl B, Baron T, Albertucci M, et al. Myocardial infarction with non-obstructive coronary artery disease. EuroIntervention. 2021; 17(11): e875–e887.
  76. Dudas K, Lappas G, Stewart S, et al. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation. 2011; 123(1): 46–52.
  77. Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010; 56(4): 254–263.
  78. Karam N, Bataille S, Marijon E, et al. Incidence, Mortality, and Outcome-Predictors of Sudden Cardiac Arrest Complicating Myocardial Infarction Prior to Hospital Admission. Circ Cardiovasc Interv. 2019; 12(1): e007081.
  79. Bagai A, Lu Di, Lucas J, et al. Temporal trends in utilization of cardiac therapies and outcomes for Myocardial infarction by degree of chronic kidney disease: a report from the NCDR chest pain-mi registry. J Am Heart Assoc. 2018; 7(24): e010394.
  80. Alsidawi S, Campbell A, Tamene A, et al. Ventricular septal rupture complicating delayed acute myocardial infarction presentation during the COVID-19 pandemic. JACC Case Rep. 2020; 2(10): 1595–1598.
  81. Holzknecht M, Klug G, Metzler B, et al. Mechanical complications after STEMI: Another collateral damage of the COVID-19 pandemic. Int J Cardiol. 2022; 348: 23–25.
  82. Bouisset F, Deney A, Ferrières J, et al. Mechanical complications in ST-elevation myocardial infarction: The impact of pre-hospital delay. Int J Cardiol. 2021; 345: 14–19.
  83. Ahmad IA, Osei E. Occupational health and safety measures in healthcare settings during COVID-19: strategies for protecting staff, patients and visitors. Disaster Med Public Health Prep. 2021 [Epub ahead of print]: 1–9.
  84. Liu Y, Yang S, Hung M, et al. Protecting healthcare workers amid the COVID-19 crisis: a safety protocol in Wuhan. Front Public Health. 2020; 8: 577499.
  85. Chieffo A, Stefanini GG, Price S, et al. EAPCI position statement on invasive management of acute coronary syndromes during the COVID-19 pandemic. EuroIntervention. 2020; 16(3): 233–246.
  86. Mahmud E, Dauerman HL, Welt FGP, et al. Management of acute myocardial infarction during the COVID-19 pandemic: a position statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). J Am Coll Cardiol. 2020; 76(11): 1375–1384.
  87. Mahmud E, Dauerman HL, Welt FGP, et al. Management of acute myocardial infarction during the COVID-19 pandemic: A Consensus Statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Catheter Cardiovasc Interv. 2020; 96(2): 336–345.
  88. Task Force for the management of COVID-19 of the European Society of Cardiology . ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J. 2022; 43(11): 1059–1103.
  89. Task Force for the management of COVID-19 of the European Society of Cardiology . European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. Eur Heart J. 2022; 43(11): 1033–1058.



Polish Heart Journal (Kardiologia Polska)